Date(s) - 30 Apr 2020
4:00 pm - 5:00 pm
Innovation applications of microphysiological systems (MPS) have been growing over the past decade, especially with respect to the use of complex human tissues for assessing safety of drug candidates – but broad industry adoption of MPS methods has not yet become a reality. This webinar will address some recent advances in MPS development and begin to explore the barriers to increased incorporation of MPS to improve drug safety assessment and to provide safer, more effective drugs into the clinical pipeline.
Panel Moderator: Mary Ellen Cosenza, NDA Partners
- Rhiannon David, MPS Lead, AstraZeneca
- Reyk Horland, VP Business Development, TissUse
- David Jacobson-Kram, Consultant, toxrox (fmr Associate Director, CDER, FDA)